Synlogic, Inc. (NASDAQ:SYBX) Short Interest Update

Synlogic, Inc. (NASDAQ:SYBX) was the target of a significant increase in short interest during the month of August. As of August 15th, there was short interest totalling 48,200 shares, an increase of 52.5% from the July 31st total of 31,600 shares. Based on an average trading volume of 16,800 shares, the short-interest ratio is presently 2.9 days. Currently, 0.7% of the company’s shares are sold short.

Hedge Funds Weigh In On Synlogic

A hedge fund recently raised its stake in Synlogic stock. Armistice Capital LLC grew its stake in shares of Synlogic, Inc. (NASDAQ:SYBX) by 75.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,055,000 shares of the biotechnology company’s stock after buying an additional 455,126 shares during the period. Armistice Capital LLC owned approximately 11.48% of Synlogic worth $4,062,000 as of its most recent filing with the Securities and Exchange Commission. 63.40% of the stock is owned by institutional investors.

Synlogic Trading Down 0.7 %

Synlogic stock opened at $1.48 on Friday. Synlogic has a 1 year low of $1.22 and a 1 year high of $7.65. The company’s 50-day moving average is $1.53 and its two-hundred day moving average is $1.68. The company has a market cap of $17.33 million, a PE ratio of -0.15 and a beta of 0.92.

About Synlogic

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.